Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.45 |
| ▸ | KDM5A | P29375 | 2/20 | 0.39 |
| ▸ | SIGLEC9 | Q9Y336 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 3/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | WNT1 | P04628 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872866 | 0.90 | KDM5A (0.40) | HRH4KDM5ASIGLEC9PIM1ADORA2B | |
| SCHEMBL5770048 | 0.90 | PIM1 (0.43) | KDM5APIM1ADORA2B | |
| SCHEMBL5768174 | 0.88 | KDM5A (0.39) | KDM5APIM1WNT1DYRK1ACDK4 | |
| SCHEMBL5772822 | 0.88 | KDM5A (0.39) | KDM5APIM1WNT1DYRK1ACDK4 | |
| SCHEMBL5873046 | 0.87 | CYP2C9 (0.43) | HRH4KDM5APIM1 | |
| SCHEMBL5769674 | 0.87 | PIM1 (0.40) | KDM5ASIGLEC9PIM1 | |
| SCHEMBL5873097 | 0.86 | KDM5A (0.39) | KDM5APIM1ADORA2BDYRK1A | |
| SCHEMBL5772558 | 0.86 | ADORA2A (0.39) | KDM5APIM1ADORA2B | |
| SCHEMBL5873060 | 0.86 | DYRK1A (0.40) | KDM5ASIGLEC9PIM1WNT1DYRK1A | |
| SCHEMBL5872880 | 0.85 | CYP2C9 (0.43) | KDM5APIM1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | HRH4 4233/4885KDM5A 2543/4885SIGLEC9 3645/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | HRH4 4233/4885KDM5A 2543/4885SIGLEC9 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.